Platform advantage

Platform companies appear well-armed to weather downturns in public equity markets based on data showing they have raised larger amounts of capital and been more prolific dealmakers compared to non-platform peers. But that hasn’t translated into better share price performance. 

A BioCentury analysis shows that platform companies raised substantially larger IPOs than non-platform companies, had larger follow-on financings and garnered larger upfront payments via out-licensing partnerships, despite the majority of the deals coming at the discovery or preclinical stage. ...